- Home
- LEGH vs CRGX Comparison
LEGH vs CRGX Comparison
Compare LEGH & CRGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEGH
- CRGX
- Stock Information
- Founded
- LEGH 2005
- CRGX 2021
- Country
- LEGH United States
- CRGX United States
- Employees
- LEGH N/A
- CRGX N/A
- Industry
- LEGH Homebuilding
- CRGX
- Sector
- LEGH Consumer Discretionary
- CRGX
- Exchange
- LEGH Nasdaq
- CRGX Nasdaq
- Market Cap
- LEGH 601.1M
- CRGX 628.6M
- IPO Year
- LEGH 2018
- CRGX 2023
- Fundamental
- Price
- LEGH $25.67
- CRGX $3.70
- Analyst Decision
- LEGH Buy
- CRGX Hold
- Analyst Count
- LEGH 2
- CRGX 7
- Target Price
- LEGH $29.00
- CRGX $4.67
- AVG Volume (30 Days)
- LEGH 59.5K
- CRGX 1.9M
- Earning Date
- LEGH 03-14-2025
- CRGX 03-20-2025
- Dividend Yield
- LEGH N/A
- CRGX N/A
- EPS Growth
- LEGH N/A
- CRGX N/A
- EPS
- LEGH 2.18
- CRGX N/A
- Revenue
- LEGH $163,718,000.00
- CRGX N/A
- Revenue This Year
- LEGH N/A
- CRGX N/A
- Revenue Next Year
- LEGH $8.19
- CRGX N/A
- P/E Ratio
- LEGH $11.66
- CRGX N/A
- Revenue Growth
- LEGH N/A
- CRGX N/A
- 52 Week Low
- LEGH $19.42
- CRGX $3.00
- 52 Week High
- LEGH $29.31
- CRGX $33.92
- Technical
- Relative Strength Index (RSI)
- LEGH 54.62
- CRGX 20.88
- Support Level
- LEGH $24.93
- CRGX $3.00
- Resistance Level
- LEGH $26.00
- CRGX $3.88
- Average True Range (ATR)
- LEGH 0.72
- CRGX 0.92
- MACD
- LEGH 0.15
- CRGX -1.00
- Stochastic Oscillator
- LEGH 70.53
- CRGX 5.99
About LEGH Legacy Housing Corporation (TX)
Legacy Housing Corp builds, sell, and finance manufactured homes and tiny houses that are distributed through a network of independent retailers and company-owned stores and also sold directly to manufactured home communities. The company also provides financing options to customers to facilitate the sale of homes.
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.